Drug manufacturer Eli Lilly & Co. has sent cease-and-desist letters to U.S. healthcare providers demanding an end to the promotion and sale of copycat versions of the company’s Mounjaro and Zepbound GLP-1 drugs, Bloomberg reported Aug. 15.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
